Bidirectional Genetic Link Between Graves’ Disease and Rheumatoid Arthritis: Microbiome & Clinical Insights Original paper
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass
What was studied?
This original Mendelian randomization (MR) study evaluated the bidirectional causal relationship between Graves’ disease (GD) and rheumatoid arthritis (RA). Using genome‑wide association study (GWAS) summary statistics from BioBank Japan, the authors selected single‑nucleotide polymorphisms (SNPs) associated with each disease as instrumental variables and applied inverse‑variance–weighted, MR‑Egger, and weighted‑median models to infer causality.
Who was studied?
The analysis drew on 2,176 GD cases, 4,199 RA cases, and >208,000 population controls of East‑Asian ancestry. All participants were genotyped within BioBank Japan; supplemental RA data (4,873 cases, 17,642 controls) were included to test robustness. Because only East‑Asian datasets were used, findings chiefly reflect genetic architecture in this population.
Most important findings
The MR framework showed a 39 % genetically mediated increase in GD risk among individuals predisposed to RA (OR 1.39, 95 % CI 1.10–1.75; p = 0.007) and a 30 % increase in RA risk among those genetically predisposed to GD (OR 1.30, 95 % CI 0.94–1.80; p = 0.11). Sensitivity analyses (MR‑Egger intercept, leave‑one‑out, weighted median) indicated little horizontal pleiotropy, supporting a genuine bidirectional effect.
| Autoimmune phenotype | Key microbiome signatures reported in literature* | Possible mechanistic links |
|---|---|---|
| RA | ↑ Prevotella copri, ↓ Bifidobacterium, ↑ Th17‑skewing taxa | Mucosal priming, molecular mimicry |
| GD | ↑ Prevotella, ↓ Lactobacillus/Bifidobacterium, altered Firmicutes/Bacteroidetes ratio | Enhanced gut permeability, T‑cell activation |
| Shared pattern | Enrichment of Prevotella spp.; depletion of butyrate producers | Convergent Th17 and NF‑κB signalling, systemic autoimmunity |
*Derived from recent gut‑microbiome case‑control studies of RA and GD; not measured in the present MR analysis.
Key implications
The genetic evidence that RA and GD are causally linked in both directions suggests overlapping pathophysiology that extends from host genetics to immune regulation and, plausibly, to shared gut‑microbiome dysbiosis. Clinically, clinicians should (1) screen RA patients for thyroid dysfunction and vice versa, (2) anticipate that therapies modulating common immune checkpoints (e.g., CD40, JAK–STAT, IGF‑1R) could confer cross‑disease benefit, and (3) consider microbiome‑targeted interventions as adjunctive strategies. For microbiome‑signature databases, GD and RA may be grouped under a common “Prevotella‑enriched, butyrate‑depleted” autoimmune endotype, informing future diagnostic or therapeutic biomarker development.